Enovis Corporation

ENOV Healthcare Medical Devices

Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

19.59 0.24 +1.24%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
195×
Dividend yield
—
F-score
4/9
Altman Z
−0.34
Beneish M
−4.29
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(54.27%) (55.48%) (58.40%) (51.04%)

+8 more TTM periods

Piotroski F-Score
4 4 4 4
ROA
(25.07%) (26.12%) (27.69%) (27.39%)
ROIC
(23.55%) (24.14%) (25.53%) (24.01%)
Return on Tangible Assets
(97.48%) (98.83%) (106.17%) (114.78%)
Average Days of Receivables
70.22 71.16 71.89 70.57
Free Cash Flow per Share
1.11 0.63 0.35 0.40
Free Cash Flow
63.66 35.92 19.92 22.77
Other line items

Show all line items

Columns are period end dates